JLL Capital Markets arranged the acquisition of the 76,000-square-foot 9501 Lakeside Blvd. in The Woodlands, Texas
WASHINGTON, D.C., August 24, 2022 – JLL Capital Markets announced today that it has closed the acquisition of 9501 Lakeside, a future 76,000-square-foot, cell therapy manufacturing facility located in The Woodlands within the Houston, Texas, MSA.
JLL represented the tenant, Cellipont Bioservices, and procured the buyer, Vitrian, a fully integrated biomanufacturing and cGMP real estate company.
9501 Lakeside will feature state-of-the-art manufacturing, process development, assay development and testing capabilities and is scheduled to open within the first half of 2023. The opening of this site will expand upon Cellipont’s existing location in San Diego.
The property sits in Research Forest Lakeside (“RFL”) in The Woodlands, Texas. RFL is a planned development uniquely located on 77-wooded acres overlooking Lake Woodlands that features six office and four retail buildings, with future development of up to three additional class A office buildings totaling 760,000 square feet. The mixed-use site is home to a diverse line up of tenants including chemical, financial services, logistics, oil and gas exploration, LNG shipping and integrated energy companies. RFL’s location provides easy access to all of The Woodlands’ amenities, such as Market Street, The Woodlands Mall and The Woodlands Waterway Marriott Hotel and Convention Center. Additionally, I-45 is less than a five-minute drive away.
The JLL Capital Markets Investment Advisory team representing the tenant was led by Directors Dave Baker and Brian Buglione and Managing Director Kevin McConn.
“JLL is honored to have represented Cellipont, a best-in-class cell therapy CDMO, in achieving this critical milestone in their growth trajectory,” said Baker. “Strong investor interest in this opportunity reflected the strength of Cellipont as a tenant, as well as projected growth in the cell therapy manufacturing space, and investors’ positive reception of the growing Houston life science market. We are excited to watch the future successes of Cellipont and Vitrian together.”
JLL Capital Markets is a full-service global provider of capital solutions for real estate investors and occupiers. The firm’s in-depth local market and global investor knowledge delivers the best-in-class solutions for clients — whether investment and sales advisory, debt advisory, equity advisory or a recapitalization. The firm has more than 3,000 Capital Markets specialists worldwide with offices in nearly 50 countries.
For more news, videos., and research resources on JLL, please visit our newsroom.
About JLL
JLL (NYSE: JLL) is a leading professional services firm that specializes in real estate and investment management. JLL shapes the future of real estate for a better world by using the most advanced technology to create rewarding opportunities, amazing spaces and sustainable real estate solutions for our clients, our people and our communities. JLL is a Fortune 500 company with annual revenue of $19.4 billion, operations in over 80 countries and a global workforce of more than 102,000 as of June 30, 2022. JLL is the brand name, and a registered trademark, of Jones Lang LaSalle Incorporated. For further information, visit jll.com.
About Cellipont Bioservices
Cellipont Bioservices is a privately-held cell therapy CDMO based near San Diego, California with more than 15 years of experience in the development and small-to-large batch manufacturing of cell therapies. Our team has deep technical expertise and has been recognized by customers and partners for its ability to productively grow challenging cell types. Our culture is customer-centric with a focus on partnering, flexibility and responsiveness. For more information, please visit www.cellipont.com.
About Vitrian
Vitrian is the first fully integrated real estate company dedicated exclusively to biomanufacturing and cGMP facilities. Its mission is to foster the next generation of drugs and therapies by accelerating facility procurement and development, improving the capitalization process, and building capacity for future growth through civic engagement and workforce development. For more information, please visit www.vitrian.com.
The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE
